Maat Pharma · EURONEXT:MAAT
Maat Pharma — Investor Presentation (January 2022)
29 slides from Maat Pharma's investor presentation, Jan 23, 2022
Slide 1: MaaT Pharma: Microbiota as a Therapy
MaaT Pharma Microbiota as a Therapy Company Presentation
Slide 2: Disclaimer
Disclaimer THIS PRESENTATION AND ITS CONTENTS ARE NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, JAPAN, OR ANY OTHER • The distribution of this presentation and any information contained herein in certain ju
Slide 3: A Uniquely-Positioned Microbiome Company
A Uniquely-Positioned Microbiome Company Listed on Euronext (MAAT) Pioneering development of Microbiome Ecosystem Therapies to address hematological malignancies and oncology Differentiated approach validated by compelling Phase II data in aGvHD Multi-asset pipeline (incl. 2 products in clinical tes
Slide 4: Management Team
Management Team Siân Crouzet Hervé Affagard Dr. Carole Schwintner Chief Operating Officer Founder & CEO Chief Technology Officer Dr. Savita Bernal Dr. John Weinberg Dr Isabelle Adeline Chief Business Officer Chief Medical Officer Chief of Staff Corporate Presentation January 2022 4
Slide 5: Host – Microbiota Interactions are Critical for a Functional Immune System
Host – Microbiota Interactions are Critical for a Functional Immune System A rich and diversified gut ecosystem actively modulates the immune system functionality • A diversified microbiome contributes to the education and modulation of our immune system throughout life • Bacterial richness and mucu
Slide 6: Diversity matters! Higher gut microbiome diversity is associated with …
Diversity matters! Higher gut microbiome diversity is associated with … Liquid Tumors Solid Tumors Higher survival rate in patients Lower incidence and lower Higher response rate to ICI* in patients receiving allo-HSCT *,1 mortality from aGvHD*,2 with metastatic melanoma3 -30% mortality aGvHD 1 MaaT
Slide 7: MaaT Pharma's MET platform has generated a diverse line of product candidates
MaaT Pharma’s Microbiome Ecosystem Therapy (MET) platform has generated a diverse line of product candidates Microbiome Ecosystem cGMP Therapies (MET) Platform Native Co-fermented MaaT013 MaaT033 MaaT03X ✓ Indication-specific designed ✓ High diversity ecosystem (from clinical data) ✓ Full ecosystem
Slide 8: Platform enables rapid build-up of the addressable population
MaaT Pharma’s approach and platform enable a rapid build-up of the addressable population that can benefit from its therapies MaaT013 MaaT033 MaaT03X ~ 2,000 patients1 ~ 22,000 patients1 >200,000 patients1 3rd Long-term Prevention of Melanoma, line SR Expansion 10x TAM complications >10x TAM NSCLC,
Slide 9: Hemato-Oncology
e < Eq T Hemato-Oncology ¥, . ats
Slide 10: MaaT013 and MaaT033 aim to restore the gut microbiota to improve survival in patients with liquid tumors
MaaT013 and MaaT033 aim to restore the gut microbiota to improve survival in patients with liquid tumors Intestinal dysbiosis is associated with higher mortality in hemato-oncology Chemotherapy Allogenic Hematopoietic Stem Cell Patients with liquid Antibiotics Transplantation (allo-HSCT) tumors Irra
Slide 11: Hemato-Oncology: Treatment of acute Graft-vs-host-Disease (aGvHD)
Hemato-Oncology Treatment of acute Graft-vs-host-Disease (aGvHD)
Slide 12: Two complementary approaches generating data on MaaT013
MaaT013 aGvH Two complementary approaches generating data on MaaT013 Phase 2 clinical trial - HERACLES Early Access Program/Compassionate Use (formerly « ATU ») • Phase 2 clinical trial HERACLES (NCT03359980) • Authorized by the French regulator (ANSM) • N=24 patients • N=521 patients • 4 countries
Slide 13: HERACLES Phase 2 Clinical Trial
MaaT013 Phase 2 HERACLES Phase 2 Clinical Trial Promising results in a very severe (III-IV) GI aGvHD population • N=24 patients, 96% grade III (4% grade IV) , 3 doses, 2nd line (Steroid-resistant) • Microbiota analysis shows better engraftment of MaaT013 and higher gut microbiome diversity after tre
Slide 14: Early Access Program: Promising confirmation in a severe GI aGvHD population
MaaT013 EAP Early Access Program (EAP): Promising confirmation in an advanced, severe and more diverse GI aGvHD population • N=52 patients : 83% steroid-resistant ; 94% grade III, Up to 6 lines of prior treatment (median: 3 ; 77% have received ruxolitinib); 3 doses • Good tolerability and safety pro
Slide 15: The ARES Phase III study is designed to establish MaaT013 as 3rd line agent
MaaT013 The ARES Phase III study is designed to establish MaaT013 aGvH as the 3rd line agent in GI aGvHD treatment • Pivotal single arm trial of MaaT013 as 3rd line (steroid-resistant & ruxolitinib-resistant) in n=75 GI-aGvHD patients • Primary endpoint: GI-ORR at Day28 EUROPE : USA: ✓ Study design
Slide 16: Hemato-Oncology: Allogeneic-HSCT Complication Prevention
Hemato-Oncology Allogeneic-HSCT Complication Prevention
Slide 17: Prevention of complications of allo-HSCT offers an attractive market opportunity
MaaT033 Prevention of complications of allo-HSCT offers an attractive Allo-HCT market opportunity for MaaT Pharma to address with MaaT033 • MaaT033, an oral formulation of MaaT013’s drug substance, aims to prevent complications from allo-HSCT in all patients receiving the intervention 100% United St
Slide 18: Phase Ib CIMON study concluded early, will determine MaaT033 dose
Phase Ib CIMON study concluded early, will determine MaaT033 MaaT033 Allo-HCT dose for a Phase II/III study in prevention of post-allogeneic HSCT complications Visit 1 Visit 2 Visit 3 Visit 4 Day 0 Inclusion 1 week Patients with acute myeloid leukemia after induction therapy MaaT033 treatment Consol
Slide 19: Immuno-Oncology Solid Tumors
Immuno-Oncology Solid Tumors
Slide 20: A diverse gut microbiome increases survival in patients receiving ICI
I/O A diverse gut microbiome increases survival in patients receiving immune checkpoint inhibitors (ICI) FMT from ICI responders to ICI non-responding • Immune check-point inhibitors (ICI) therapies have established patients with metastatic melanoma themselves as key therapeutic options in solid tum
Slide 21: MaaT013 ensures high diversity and contains strains that improve ICI response
MaaT013 I/O MaaT013 ensures high diversity and contains specific bacterial strains that have been identified to improve ICI response Phase IIa PICASSO trial2, in collaboration with APHP (sponsor), ready to start (approved by ANSM) ✓ RCT [MaaT013 + ICI] vs. [Placebo + ICI] in 60 metastatic melanoma p
Slide 22: Proprietary gutPrint platform generates indication-specific microbiome ecosystem therapies
MaaT03X Proprietary gutPrint® platform synergizes multi-source data to I/O generate innovative and indication-specific microbiome ecosystem therapies gutPrint® is the engine that drives MaaT Pharma’s MET product candidate generation capabilities that broaden and strengthen the pipeline Corporate Pre
Slide 23: Customizability and scalability of the MaaT03X line
MaaT03X I/O The customizability and scalability of the MaaT03X line allows it to potentially address several solid tumor indications Designable according to Customizable, donor-independent, indication-specific microbial scalable process Fermented (MaaT03X) signatures Ecosystem Full design Indication
Slide 24: Shareholding structure
e T Shareholding structure . O ¢ meh seco \S 8 HM,
Slide 25: MaaT Pharma is listed on Euronext Paris – 35.7M€ IPO Nov. 2021
Governance MaaT Pharma is listed on Euronext Paris – 35.7M€ IPO Nov. 2021 BOARD OF DIRECTORS Jean-Marie Lefèvre Chairman & Non-Executive Director President - Biocodex 9,46% 19,61% Isabelle de Crémoux Non-Executive Director CEO & Managing Partner - Seventure 13,66% Claude Bertrand Non-Executive Direc
Slide 26: Key Upcoming Milestones
‘e T Key Upcoming Milestones O ¢ | meh seco \S 2 HM,
Slide 27: Development plan produces a steady flow of value-creating news
MaaT Pharma’s development plan produces a steady flow of meaningful and value-creating news in both the near and long term Intermediate review 2021 2022 2023 2024 2025 Results Launch H2 H2 H1 H2 H1 H2 H1 H2 H1 H2 Graft-vs-Host-Disease MaaT013 (pooled enema) Phase III ARES ORR Overall FDA & EMA Orpha
Slide 28: Key differentiators of MaaT Pharma from other microbiome competitors
Key differentiators of MaaT Pharma from other microbiome competitors Full ecosystem Manufacturing approach versatility MaaT Pharma pioneers a full Internal competencies enable ecosystem approach instead of manufacturing scalability via single strain or consortia to native or co-fermented cGMP restor
Slide 29: Thank You
THANK YOU 29